Jonathan B Grimm

USPTO Granted Patents = 18 (Patent Applications = 7)

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 9 (Patent Applications = 6)

Average Co-Inventor Count = 5.1

ph-index = 4

Forward Citations = 60(Granted Patents)

Location History:

Newton, MA (US) (2011 - 2013)
Ashburn, VA (US) (2016 - 2024)

Company Filing History:

9 out of 2,405

Merck Sharp + Dohme Corp.

patents

9 out of 118

Howard Hughes Medical Institute

where one patent can have more than one assignee

Years Active: 2011-2025

Loading Chart...

18 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12344594 - Red-shifted fluorophores (2025-07-01),

2. 11958976 - Photoactive fluorophores and methods of in vivo labeling (2024-04-16),

3. 11787946 - Deuterated fluorophores (2023-10-17),

4. 11091643 - Deuterated fluorophores (2021-08-17),

5. 10495632 - Azetidine-substituted fluorescent compounds (2019-12-03),

6. 10407399 - Ion-activated photolabile compounds (2019-09-10),

7. 10161932 - Azetidine-substituted fluorescent compounds (2018-12-25),

8. 10018624 - Azetidine-substituted fluorescent compounds (2018-07-10),

9. 9933417 - Azetidine-substituted fluorescent compounds (2018-04-03),

10. 9745295 - Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors (2017-08-29),

11. 9586931 - Triazolyl derivatives as Syk inhibitors (2017-03-07),

12. 9487504 - Imidazolyl analogs as syk inhibitors (2016-11-08),

13. 9290490 - Aminopyrimidines as Syk inhibitors (2016-03-22),

14. 8367706 - Inhibitors of janus kinases (2013-02-05),

15. 8344144 - Inhibitors of Janus kinases (2013-01-01),

Title: Innovations of Jonathan B. Grimm in Fluorophore Development

Introduction

Jonathan B. Grimm is an accomplished inventor based in Ashburn, VA, with a remarkable portfolio of 18 patents to his name. His work primarily revolves around the development of advanced compounds and methods that greatly contribute to the field of fluorescence and imaging technologies.

Latest Patents

Among his latest innovations, Grimm has introduced breakthroughs in the realm of red-shifted fluorophores, which offer enhanced capabilities for in vivo labeling. This includes a compound structure that encompasses photoactive fluorophores, along with a photoactive ligand and photoactive complex. These inventions incorporate a photoactivatable derivative of an azetidine-containing Janelia-Fluor dye, providing researchers with powerful tools for biological imaging. Furthermore, his methods facilitate in vivo labeling and photoactivation, expanding the utility of these advanced fluorophores significantly.

Career Highlights

Jonathan B. Grimm has made substantial contributions throughout his career, particularly during his tenure with renowned organizations such as Merck Sharp & Dohme Corporation and the Howard Hughes Medical Institute. These experiences have empowered him to pivot his academic insights into practical, innovative applications that benefit various scientific fields.

Collaborations

Throughout his illustrious career, Grimm has collaborated with several talented individuals, including Luke D. Lavis and Kevin J. Wilson. These partnerships have sparked innovation and allowed for the exchange of ideas that enhance research outcomes in their respective domains.

Conclusion

Jonathan B. Grimm's endeavors in the development of photoactive fluorophores and related technologies showcase his significant impact on scientific research and innovations. His 18 patents and collaborations highlight his commitment to advancing the field, establishing him as a notable figure in the scientific community.

This text is generated by artificial intelligence and may not be accurate.